65
Participants
Start Date
May 31, 2007
Primary Completion Date
August 8, 2010
Study Completion Date
August 8, 2010
Marqibo® (vincristine sulfate liposomes injection)
Dosing was done every 7 days (± 3 days) on Days 1, 8, 15, and 22 with no less than 4 days between dosing days. Dose calculations were based on body surface area using the subject's height (from Screening) and actual weight for each course.
New York Medical College, Valhalla
Roswell Park Cancer Institute, Buffalo
Western Pennsylvania Allegheny Health System, Pittsburgh
University of Pittsburgh Medical Center, Pittsburgh
University of Rostock, Rostock
Emory University - Winship Cancer Institute, Atlanta
Rambam Medical Center, Haifa
University of Essen, Essen
University of Muenster, Münster
Henry Ford Health System, Detroit
Rabin Medical Center Campus, Petah Tikva
Univesity of Iowa - Hospitals and Clinica, Iowa City
Loyola University Medical Center, Chicago
J.W. Goethe University, Frankfurt
Rush University Medical Center, Chicago
University of Chicago Medical Center, Chicago
University of Nebraska Medical Center, Omaha
Diakonie-Klinikum Stuttgart, Stuttgart
University of Texas M.D. Anderson Cancer Center, Houston
Rocky Mountain Cancer Center, Denver
University of Ulm, Ulm
USC - Norris Cancer Center, Los Angeles
UCLA Medical Center, Los Angeles
Hadassah Medical Center - Ein Karem, Jerusalem
University of California Medical Center, San Francisco
Stanford Hospitals and Clinics, Stanford
Hackensack University Medical Center, Hackensack
Princess Margaret Hospital, Toronto
Dresden University Hospital, Dresden
University of Leipzig, Leipzig
Robert Bosch Hospital, Stuttgart
The Chaim Sheba Medical Center, Tel Litwinsky
Derriford Hospital, Plymouth
Collaborators (1)
Parexel
INDUSTRY
Spectrum Pharmaceuticals, Inc
INDUSTRY